Hypersensitivity reactions to oxaliplatin and other antineoplastic agents.
Although the reported incidence of hypersensitivity reactions (HSR) to antineoplastic agents is considered to be uncommon, it is difficult to evaluate their exact prevalence, mainly because their definition is vast and pathogenic mechanisms are vague. HSR include facial flushing, erythema, pruritus, fever, tachycardia, dyspnea, tongue swelling, rash/hives, headache, chills, weakness, vomiting, burning sensations, dizziness, and edema. Treatment and prevention consists of slowing the infusion rate, steroids, and type 1 and 2 histamine receptor antagonists. Desensitization could allow the small number of patients who experience severe HSR to receive effective therapy for their cancer. Reintroductions have only been reported as single case studies or small cohorts. Large-scale validation on desensitization strategies is still missing. With regard to oxaliplatin, knowledge of its rare but eminent toxicity is paramount, because this drug is widely used in treating colorectal cancer, the second-highest cause of cancer mortality in the United States.
Syrigou
Ekaterini
E
Section of Medical Oncology, Yale University School of Medicine, 333 Cedar Street, FMP:116, New Haven, CT 06520, USA.
Syrigos
Kostas
K
Saif
M Wasif
MW
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000276:immunology; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D015994:Incidence; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000276:immunology*; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin